Dr Lal PathLabs beats the Road, declares dividend of ₹6 as Q1 web revenue surges 30%

Diagnostic providers supplier Dr Lal PathLabs Ltd on Wednesday (August 7) reported a 30% year-on-year (YoY) surge in web revenue at ₹107.8 crore for the primary quarter that ended June 30, 2024.

Within the corresponding quarter, Dr Lal PathLabs posted a web revenue of ₹82.6 crore, the corporate stated in a regulatory submitting. The CNBC-TV18 ballot had predicted a revenue of ₹93.2 crore for the quarter below evaluate.

The corporate’s income from operations elevated 11.3% to ₹601.9 crore  towards ₹541 crore within the corresponding interval of the previous fiscal. The CNBC-TV18 ballot had predicted income of ₹598.2 crore for the quarter below evaluate.

Additionally Learn: PI Industries Q1 Outcomes | Agrochem agency tops estimates, posts 17% rise in web revenue

On the working stage, EBITDA elevated 16.3% to ₹170 crore within the first quarter of this fiscal over ₹146.2 crore within the corresponding interval within the earlier fiscal. The CNBC-TV18 ballot had predicted an EBITDA of ₹163.2 crore for the quarter below evaluate.

The EBITDA margin stood at 28.2% within the reporting quarter in comparison with 27% within the corresponding interval within the earlier fiscal. EBITDA is earnings earlier than curiosity, tax, depreciation, and amortisation. The CNBC-TV18 ballot had predicted a margin of 27.3% for the quarter below evaluate.

The board of administrators declared an interim dividend of ₹6 per fairness share (or 60% on a face worth of ₹10 every) for the monetary yr 2024-25. The report date for the aim of cost of the interim dividend shall be August 20, 2024. The interim dividend will likely be credited inside 30 days of its declaration.

Additionally Learn: Aditya Birla Vogue Retail Q1 Outcomes | Internet loss widens to ₹161 crore regardless of income bounce

Dr Om Manchanda, Managing Director, stated, “Moreover, we’re creating medical centres of excellence to make sure correct and well timed analysis, thereby enhancing constructive affected person outcomes for recognized underlying circumstances. The following leg of outreach is coming from our growth efforts in tier 3 and 4 cities, the place we’re creating infrastructure apace.”

The outcomes got here after the shut of the market hours. Shares of Dr Lal PathLabs Ltd ended at ₹3,268.85, up by ₹ 100.40, or 3.17%, on the BSE.

(Edited by : Shoma Bhattacharjee)